The Systemic Mastocytosis drugs in development market research report provides comprehensive information on the therapeutics under development for Systemic Mastocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Systemic Mastocytosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Systemic Mastocytosis by nine companies/universities/institutes. The top development phase for Systemic Mastocytosis is phase ii with four drugs in that stage. The Systemic Mastocytosis pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Systemic Mastocytosis pipeline products market are: Blueprint Medicines, MacroGenics and AB Science.
The key targets in the Systemic Mastocytosis pipeline products market include Mast/Stem Cell Growth Factor Receptor Kit, Interleukin 3 Receptor Subunit Alpha, and Platelet Derived Growth Factor Receptor Alpha.
The key mechanisms of action in the Systemic Mastocytosis pipeline product include Mast/Stem Cell Growth Factor Receptor Kit Inhibitor with four drugs in Phase III. The Systemic Mastocytosis pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Systemic Mastocytosis pipeline products market including Small Molecule, and Antisense Oligonucleotide.
Systemic Mastocytosis overview
Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing, and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of medication, including interferon or chemotherapeutic agents.
For a complete picture of Systemic Mastocytosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
